European OTC Results Round-Up: HRA Pharma, Boiron and Ipsen

HRA Pharma reports impressive sales growth in 2018, thanks largely to acquisitions. A drop in demand for homeopathic medicines hurts Boiron in Q1, while Ipsen enjoys a solid start to the year.